美國居民不適用 XM 服務。
T
T

Teva


財經新聞

Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine

BRIEF-Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine July 18 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES FIRST PHASE 3 EVIDENCE OF EFFICACY AND SAFETY OF AN ANTI-CGRP MONOCLONAL ANTIBODY
T

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

UPDATE 2-US DOJ drops Viatris unit Mylan from industry-wide antitrust probe Adds background in paragraphs 2,5 and 6, updates share movement July 2 (Reuters) - Viatris VTRS.O u nit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry , the parent company said on Tuesday.
P
T

FTC starts probe into Teva about some products' patents, Washington Post reports

UPDATE 2-FTC starts probe into Teva about some products' patents, Washington Post reports Adds Teva comment in penultimate paragraph, background in last paragraph July 1 (Reuters) - The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical TEVA.TA over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
T

Drugmaker Servier loses EU court fight over pay-for-delay deals

UPDATE 1-Drugmaker Servier loses EU court fight over pay-for-delay deals Adds details By Foo Yun Chee BRUSSELS, June 27 (Reuters) - French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva TEVA.TA , Unichem and its subsidiary Niche, Matr
T

EU top court rejects Servier appeal against EU antitrust fine

EU top court rejects Servier appeal against EU antitrust fine BRUSSELS, June 27 (Reuters) - Europe's top court on Thursday rejected French drugmaker Servier's appeal against a finding by EU antitrust regulators a decade ago that its pay-for-delay deals with generic rivals were anti-competitive. "The Court dismisses the appeals of Lupin, Niche Generics, Unichem Laboratories, Matrix, Teva and Biogaran.
T

Alert wrongly tagged to Teva Pharmaceutical withdrawn

ADVISORY-Alert wrongly tagged to Teva Pharmaceutical withdrawn An alert on Deckers Brands' DECK.N unit Teva was incorrectly tagged to Teva Pharmaceutical Industries TEVA.TA , TEVA.N , an unrelated company, and has been withdrawn. There will be no substitute. STORY_NUMBER: nTUABMJBL2 STORY_DATE: June 26, 2024 STORY_TIME: 01:00:13 PM GMT
T

Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020

BRIEF-Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020 June 25 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA REACHES AGREEMENT WITH THE ISRAEL TAX AUTHORITY TO RESOLVE ALL PENDING LITIGATION FOR THE COMPANY'S TAXABLE YEARS 2008-2020 TEVA: WILL PAY A TOTA
T

Teva settles tax dispute in Israel with $750 mln payment

UPDATE 1-Teva settles tax dispute in Israel with $750 mln payment Adds details in paragraphs 3 & 4 June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday. Under the agreement, Teva will pay $750 million in installments between 2024 and 2029. In future, if Teva pays dividends on, or repurchases, its equity interests, th
T

Teva reaches agreement to resolve pending tax litigations for $750 million

Teva reaches agreement to resolve pending tax litigations for $750 million June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said on Tuesday it has entered an agreement with the Israel Tax Authority to resolve all pending litigation regarding taxes payable for the years from 2008 to 2020. Under the agreement, the Israel-based company will
T

US law firm Motley Rice appeals $396 mln opioid fee award

US law firm Motley Rice appeals $396 mln opioid fee award By Brendan Pierson June 24 (Reuters) - U.S. law firm Motley Rice is appealing its award of $396 million for its work on litigation against the drug industry over the opioid crisis that resulted in $46 billion in nationwide settlements. The firm said it would appeal the award, which represents 18.6% of a $2.13 billion pool of fees to be divided among dozens of law firms, in a notice filed Friday in Cleveland federal court.
T
W
M

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .
H
T

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.
H
T

Teva Announces Launch Of Authorized Generic Of Victoza In The U.S.

BRIEF-Teva Announces Launch Of Authorized Generic Of Victoza In The U.S. June 24 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF VICTOZA® (LIRAGLUTIDE INJECTION 1.8MG), IN THE UNITED STATES TEVA: LIRAGLUTIDE INJECTION IS INDICATED TO IMPROVE GLYCEMIC CONTROL IN ADULTS AND PEDIATRIC PATIENTS A
T

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit By Mike Scarcella June 17 (Reuters) - Drugmaker Apotex has sued its rival Amarin > in federal court in New Jersey, accusing it of thwarting competition for a generic version of its heart drug Vascepa and causing wholesalers and other buyers to pay artificially higher prices. The lawsuit , filed on Friday, said Amarin “has engaged in a calculated anticompetitive scheme” for more than a decade to protect Vascepa from drugmakers
B
T

Teva in talks to settle US lawsuit alleging MS drug kickbacks

Teva in talks to settle US lawsuit alleging MS drug kickbacks By Nate Raymond BOSTON, June 17 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA said it is in active talks to settle a U.S. Department of Justice lawsuit alleging it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone.
R
T

Teva sues Corcept over mifepristone 'monopoly' for rare disorder

Teva sues Corcept over mifepristone 'monopoly' for rare disorder By Mike Scarcella June 13 (Reuters) - Teva Pharmaceuticals TEVA.TA sued rival drugmaker Corcept Therapeutics CORT.O in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.
T

Amneal, US FTC win order removing Teva inhaler patents from FDA list

Amneal, US FTC win order removing Teva inhaler patents from FDA list By Blake Brittain June 10 (Reuters) - Drugmaker Amneal Pharmaceuticals AMRX.O with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical TEVA.TA patents from a U.S. Food and Drug Administration list of patents covering Teva's breathing drug ProAir HFA.
T

Top law firms in US opioid lawsuits to get hundreds of millions in fees

Top law firms in US opioid lawsuits to get hundreds of millions in fees By Brendan Pierson June 7 (Reuters) - A court-appointed panel on Friday recommended how to divvy up a pool of $2.13 billion in legal fees from nationwide drug industry settlements over the U.S. opioid crisis, with top firms set to receive hundreds of millions of dollars. The panel gave national firm Motley Rice the largest share, with 18.6% of the funds, or $396 million.
T
W
M

AbbVie's tight grip on Humira market raises concerns about biosimilars

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
A
C
P
T
F

Teva Announces Austedo® Xr (Deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved As A One Pill, Once-Daily Treatment Option

BRIEF-Teva Announces Austedo® Xr (Deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved As A One Pill, Once-Daily Treatment Option May 29 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : ANNOUNCES AUSTEDO® XR (DEUTETRABENAZINE) EXTENDED-RELEASE TABLETS NOW U.S. FDA APPROVED AS A ONE PILL, ONCE-DAILY TREATMENT OPTION FOR CLINICALLY THERAPEUTIC DOSES (24–48 MG/DAY) U.S.
T



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明